Immunotherapy in asthma

Research output: Contribution to journalArticle

Abstract

Since both allergic asthma and allergic rhinitis are inflammatory respiratory responses, study of a nasal challenge model should help elucidate mediator release in the allergic diathesis of the lower airway. Total allergen load and "priming" are significant factors in nasal and bronchial reactivity. In IgE-mediated allergic reactions, an immediate early response is followed by a delayed response, with symptoms persisting after exposure to the allergen. With immunotherapy, IgG titers rise, and the clinical response reflects a balance between the protective IgG response and the IgE-mediated allergic response. In the model studied, mast cell activation and mediator release correlated with the onset of early-phase allergic symptoms. By reducing the magnitude of mediator release and the severity of symptoms, immunotherapy may be used along with environmental controls and pharmacologic therapy to "turn off" the allergic reaction.

Original languageEnglish (US)
Pages (from-to)554-562
Number of pages9
JournalThe Journal of Allergy and Clinical Immunology
Volume83
Issue number2 PART 2
DOIs
StatePublished - 1989

Fingerprint

Nose
Immunotherapy
Allergens
Immunoglobulin E
Hypersensitivity
Asthma
Immunoglobulin G
Disease Susceptibility
Mast Cells
Therapeutics
Allergic Rhinitis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Immunotherapy in asthma. / Creticos, Peter Socrates.

In: The Journal of Allergy and Clinical Immunology, Vol. 83, No. 2 PART 2, 1989, p. 554-562.

Research output: Contribution to journalArticle

@article{7ad003c2b2ec477fa49145c4160c0839,
title = "Immunotherapy in asthma",
abstract = "Since both allergic asthma and allergic rhinitis are inflammatory respiratory responses, study of a nasal challenge model should help elucidate mediator release in the allergic diathesis of the lower airway. Total allergen load and {"}priming{"} are significant factors in nasal and bronchial reactivity. In IgE-mediated allergic reactions, an immediate early response is followed by a delayed response, with symptoms persisting after exposure to the allergen. With immunotherapy, IgG titers rise, and the clinical response reflects a balance between the protective IgG response and the IgE-mediated allergic response. In the model studied, mast cell activation and mediator release correlated with the onset of early-phase allergic symptoms. By reducing the magnitude of mediator release and the severity of symptoms, immunotherapy may be used along with environmental controls and pharmacologic therapy to {"}turn off{"} the allergic reaction.",
author = "Creticos, {Peter Socrates}",
year = "1989",
doi = "10.1016/0091-6749(89)90037-7",
language = "English (US)",
volume = "83",
pages = "554--562",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2 PART 2",

}

TY - JOUR

T1 - Immunotherapy in asthma

AU - Creticos, Peter Socrates

PY - 1989

Y1 - 1989

N2 - Since both allergic asthma and allergic rhinitis are inflammatory respiratory responses, study of a nasal challenge model should help elucidate mediator release in the allergic diathesis of the lower airway. Total allergen load and "priming" are significant factors in nasal and bronchial reactivity. In IgE-mediated allergic reactions, an immediate early response is followed by a delayed response, with symptoms persisting after exposure to the allergen. With immunotherapy, IgG titers rise, and the clinical response reflects a balance between the protective IgG response and the IgE-mediated allergic response. In the model studied, mast cell activation and mediator release correlated with the onset of early-phase allergic symptoms. By reducing the magnitude of mediator release and the severity of symptoms, immunotherapy may be used along with environmental controls and pharmacologic therapy to "turn off" the allergic reaction.

AB - Since both allergic asthma and allergic rhinitis are inflammatory respiratory responses, study of a nasal challenge model should help elucidate mediator release in the allergic diathesis of the lower airway. Total allergen load and "priming" are significant factors in nasal and bronchial reactivity. In IgE-mediated allergic reactions, an immediate early response is followed by a delayed response, with symptoms persisting after exposure to the allergen. With immunotherapy, IgG titers rise, and the clinical response reflects a balance between the protective IgG response and the IgE-mediated allergic response. In the model studied, mast cell activation and mediator release correlated with the onset of early-phase allergic symptoms. By reducing the magnitude of mediator release and the severity of symptoms, immunotherapy may be used along with environmental controls and pharmacologic therapy to "turn off" the allergic reaction.

UR - http://www.scopus.com/inward/record.url?scp=0024517943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024517943&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(89)90037-7

DO - 10.1016/0091-6749(89)90037-7

M3 - Article

C2 - 2645352

AN - SCOPUS:0024517943

VL - 83

SP - 554

EP - 562

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2 PART 2

ER -